April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Inhibition of Choroidal Neovascularization by the Synthetic Oleanane Triterpenoid CDDO-Im
Author Affiliations & Notes
  • Ian F. Pitha
    Ophthalmology, Barnes Hosptial/Washington University in St. Louis, St. Louis, Missouri
  • Michael B. Sporn
    Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire
  • Rajendra S. Apte
    Ophthalmology, Washington University in St. Louis, St. Louis, Missouri
  • Footnotes
    Commercial Relationships  Ian F. Pitha, None; Michael B. Sporn, Reata Pharmaceuticals (P); Rajendra S. Apte, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4879. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ian F. Pitha, Michael B. Sporn, Rajendra S. Apte; Inhibition of Choroidal Neovascularization by the Synthetic Oleanane Triterpenoid CDDO-Im. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4879.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Synthetic oleanane triterpenoids (SO) are natural plant product derivatives with potent anti-inflammatory and anti-oxidant activity in diverse in vitro and in vivo settings. Recent evidence showed anti-angiogenic activity of these compounds. These studies test the ability of the SO, CDDO-Im to inhibit pathologic angiogenesis in a preclinical model of choroidal neovascularization (CNV).

Methods: : 6 week old C57Bl/6J, female mice were treated with the SO CDDO-Im or vehicle control by daily, intraperitoneal injection. On day 3 of treatment, CNV was induced by rupture of Bruchs membrane using a krypton red laser. Treatment was continued until day 11. CNV was then visualized using fluorescein angiography and threshold CNV area was quantified using digital imaging software. Average CNV area and standard error were calculated. Significance was determined by Student's t-test analysis.

Results: : CDDO-Im inhibited CNV formation in a dosage dependent manner. Average CNV area in control mice was (8424±870 threshhold units (tu)). Mice treated with 3 micromole/kg mouse weight CDDO-Im had significantly reduced CNV area (4284±810 tu, p=0.0011) while mice treated with 0.3 micrograms/kg (5807±885 tu, p=0.056) did not display significant reduction in CNV.

Conclusions: : The SO, CDDO-Im inhibits pathologic angiogenesis in a preclinical model of CNV formation. Further studies are required to determine the molecular mechanisms and clinical potential of SO in treatment of pathologic CNV.

Keywords: age-related macular degeneration • choroid: neovascularization • neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.